Evaluation Pembrolizumab (Keytruda): CADTH Reimbursement Suggestion: Indication: In combination with chemotherapy, for that remedy of Grownup patients with locally recurrent unresectable or metastatic triple-adverse breast most cancers which have not obtained prior chemotherapy for metastatic condition and whose tumours Convey programmed cell Dying